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Abstract
Background: Alzheimer’s disease (AD) is one of the leading causes of death in the US and there is no validated drugs
to stop, slow or prevent AD. Despite tremendous effort on biomarker discovery, existing findings are mostly individual
biomarkers and provide limited insights into the transcriptomic decoupling underlying AD. We propose to explore
the gene co-expression patterns in multiple AD stages, including cognitively normal (CN), early mild cognitive
impairment (EMCI), late MCI and AD.
Methods: Wemodified traiditonal joint graphical lasso to model our asusmption that the co-expression networks in
consecutive disease stages are largely similar with critical differences. In addition, we performed subsequent network
comparison analysis for identification of stage specific transcriptomic decoupling. We focused our analysis on top
AD-enriched pathways.
Results: We observed that 419 edges in CN, 420 edges in EMCI, 381 edges in LMCI and 250 edges in AD were
frequently estimated with non zero weights. With modified JGL, the weight of all estimated edges in CN, EMCI and
LMCI are zero. In AD group, 299 edges were occasionally estimated to be nonzero and the average correlation
between genes was 0.0023. For co-expression change during AD progression, there are 66 pairs of genes that
demonstrated a continuously decreasing or increasing co-expression from CN to EMCI, LMCI and AD.The network
level clustering coefficient remains stable from CN to LMCI and then decreases significantly when progressing to AD.
When evaluating edge level differences, we identified eight gene modules with continuously decreasing or increasing
co-expression patterns during AD progression. Five of them shows significant changes from CN to EMCI and thus
have the potential to serve system biomarkers for early screening of AD.
Conclusion: We employed a modified joint graphical lasso for estimation of co-expression networks for multiple
stages of AD. Comparing with graphical lasso, our modified joint graphical lasso model accounts for the similarity in
consecutive disease stages. Our results on real data set revealed five gene clusters with obvious co-expression pattern
change from CN to EMCI, which could be used as potential system-level biomarkers for early screening of AD.
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Background
Alzheimer’s disease (AD) is a major neurodegenerative
disorder that has been characterized by gradual memory
loss and brain behavior impairment. According to the lat-
est report [1], an estimated number of 5.7 million aging
Americans are living with Alzheimer’s and this number
is expected to escalate in coming years given the rapid
increase of aging population. To prevent this public health
crisis, tremendous effort has been dedicated to discov-
ery of effective AD biomarkers. In addition to APOE e4
alleles known as major genetic determinants [2], large-
scale genome-wide association studies (GWAS) have led
to identification ofmany novel genetic risk locus [3]. How-
ever, extant work largely investigated genetic variations
or individual genes associated with AD. Very few studies
paid attention to the interactions and associations among
the gene products and how they are gradually disrupted
during AD progression [4, 5].
Gene co-expression networks describes the correlation
patterns among genes. Differential co-expression analysis
examines the altered patterns between co-expression net-
works of two states, e.g., healthy controls vs. patients. It
has great potential to identify the gene clusters affected
by stage transition and therefore provide valuable infor-
mation on how the biological system alters during dis-
ease progression. According to the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) project, subjects usually
progress from cognitive normal (CN) status (i.e., those
without any signs of depression, dementia or cognitive
impairment), to early mild cognitive impairment (EMCI),
late mild cognitive impairment (LMCI) (i.e., those with
deteriorating memory concerns, but not decline in per-
forming daily activities and no signs of dementia), and
finally AD. In this project, we propose to perform a differ-
ential co-expression analysis across all the stages of AD,
including CN, EMCI, LMCI and AD.
One common method to generate co-expression net-
work is through pairwise Pearson’s correlation and
WGCNA is the widely used package for co-expression
analysis [6], which is based on marginal correlation.
Although frequently used, these methods do not dis-
tinguish direct relationships from indirect relationships,
e.g., two genes that show similar co-expression patterns
due to a common intermediate gene. Unlike these meth-
ods, graphical lasso models the joint distribution of genes
and can infer the direct relationships by capturing the
conditional independence between genes [7]. A graph
generated from graphical lasso, where genes are repre-
sented as nodes and their co-expression are represented as
edges, provides valuable insights into the transcriptomic
coupling under specific condition and therefore can help
with generating new biological hypothesis. However, it
can only estimate one network at a time. When applied
to differential co-expression analysis, they estimate the
network for each group separately by treating them as
independent. This assumption clearly does not hold in
disease research since disease formation is a progres-
sive procedure. Co-expression networks in consecutive
disease stages should be largely similar with critical differ-
ences. For example, co-expression networks in CN group
and EMCI group are expected to be largely similar with
critical differences. Toward this, we propose to employ
joint graphical Lasso [8] for simultaneous estimation of
co-expression networks in multiple disease stages. A joint
analysis borrows the strength of the relatedness across
disease stages and can potentially reveal the differential
co-expression patterns with increased statistical power,
which is useful especially when the sample size is very
limited.
Given the increasing interest in and evidence of blood-
based AD biomarkers [9–12], we focused our analysis on
the plasma expression data of genes in top AD-enriched
pathways highlighted in [13]. We first estimated the co-
expression networks of all diagnosis groups using our
modified JGL to better model our assumption of net-
work similarity between consecutive disease stages. Sub-
sequently, we performed a comprehensive network com-
parison analysis of co-expression networks using edge-
level, node-level and network-level metrics. We used
global clustering coefficient to identify structural property
of each network. Node and edge centrality values were cal-
culated to allow comparison of basic network components
present in the network [14] and identification of critical
network entities [15]. Finally, we were able to identify eight
gene clusters showing gradual changes during the pro-
gression of AD. Five of them shows significant changes
from CN to EMCI and therefore have the potential to
serve as system level biomarkers for early screening of AD.
Methods
Dataset
All the plasma microarray data used in this study were
directly obtained from the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) project (http://adni.loni.usc.
edu). Raw expression values obtained directly from CEL
files were pre-processed using the Robust Multi-chip
Average (RMA) normalization method. The RMA nor-
malized expression array data further went through sev-
eral quality control (QC) steps [16]. First, we checked
the sex of samples using sex-specific gene expression
data, including XIST and USP9Y. Second, sample iden-
tity was verified on the basis of expression profiling to
Omni2.5M genotype match using a Bayesian method
to predict individual SNP genotypes from gene expres-
sion data. Detailed data description and the preprocess-
ing steps can be found in ADNI LONI website (http://
adni.loni.usc.edu). We focused our analysis on five AD-
enriched pathways highlighted in [13]. For each pathway,
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we extracted all the involved genes from Metacore. In
total, there are 75 genes included in this study (Table 1).
In the microarray data, if there are multiple probes cor-
responding to the same gene, we choose the probe with
the maximum mean expression to represent the gene.
Gene expression values were adjusted for RNA integrity
Number (RIN), baseline age and sex to remove poten-
tial bias. Finally, 662 ADNI 1 subjects without missing
gene expression values were included. Shown in Table 2 is
the detailed demographic information of all subjects. We
will jointly learn the gene co-expression networks for four
consecutive disease stages.
Joint graphical lasso
We first briefly introduce the graphical lasso method [7].
Suppose we have the expression data of p genes for n
subjects in K diagnostic groups. Denote the gene expres-
sion profile for k-th group as X(k) ⊆ nk×p, where nk is
the number of subjects in k-th group and k = 1, . . . ,K .
Assuming that the gene expression levels within each
group x(k)1 , x(k)2 , · · · , x(k)n are independent and identically
distributed with the positive definite p × p covariance
matrix k . The values in the covariance matrix reveal
how the expression of two genes vary together; the inverse
covariance matrix −1k indicates the conditional indepen-
dence between pairs of genes. Zero values in the inverse
Table 1 75 genes involved in AD enriched pathways
Pathway Genes Total
Immune response-Alternative
complement pathway
C3, CD46, CD55, CD59, CLU,
CR1, ITGAM, ITGAX
8
Development-Neurotrophin
family signaling
MAPK3, BAX, BRAF, GAB1,
GRB2, HRAS, JUN, MAGED1,
MAP2K1, MAP2K2, MAP3K1,
MAPK1,MAPK8, PIK3R1,
PIP5K1A, PTPN11, RAC1,
RAF1, RAP1A, RAPGEF1,
SHC1, SORT1, SOS1,
TP53,AK1
25
Neurophysiological
process-NMDA-dependent
postsynaptic long-term poten-
tiation in CA1 hippocampal
neurons
AKT1, BRAF, CALM1, CREB1,
EIF4E, GRB2, HRAS, MAP2K1,
MAP2K2, MAPK1, MAPK3,
MKNK1, PIK3R1 , PRKACA,
RAP1A, RAPGEF3, RPS6KA1,
RPS6KB1, SHC1, XYLT2
20
Cell adhesion-Ephrin signaling ADAM10, CDC42, EPHA1,
EPHB1, FYN, GRB10, HRAS,
KALRN, MAP3K7, MAP4K4,
MAPK8, NCK1, NCK2, PAK1,
PXN, RAC1, RAF1, RAP1A,
RASA1, RHOA, SLA, SLC10A3,
SRC, GRB2
24
Neurophysiological process-
nNOS signaling in neuronal
synapses
CALM1, CALM2, CALM3,
DLG4, GRIN2C, GRINA,
PPP3CA PPP3CB, PPP3CC,
PPP3R1, PRKCB, PRKCD,
PRKCH, PRKCI, PRKD3
15
Table 2 Demographic information of participants
Groups Total(N) Gender (M/F) Age (Mean± Std)
CN 225 113/112 76.65±6.16
EMCI 193 105/88 79.26±7.35
LMCI 202 127/75 76.38±7.89
AD 42 27/15 75.69±9.46
covariance matrix −1k indicates conditionally indepen-
dence of corresponding gene pairs. That is, two genes are
independent of each other after removing the effect of all
other genes in the data set.
Traditional graphical lasso estimates individual co-
expression networks separately by solving Eq. 1:
min
(k)
− log det(k) + trace (S(k)(k)) + λ1||(k)||1)
(1)
Where S(k) = (X(k))T X(k) is the empirical covariance
matrix. ||(k)||1 is the L1 norm. (k) is the inverse covari-
ance matrix (i.e., co-expression network) to be estimated
for k-th group. λ1 is the non-negative tuning parameter to
enforce the sparsity of estimated co-expression network.
However, multiple groups may be related and ignor-
ing the common structures shared across groups will
inevitably yield sub-optimal results. To address this prob-
lem, joint graphical lasso (Eq. 2) was later proposed to
enable the estimation of multiple related inverse covari-
ance matrices together through maximizing penalized log
likelihood [8]. It borrows the strength of the relatedness
across groups and can potentially reveal the differential
co-expression patterns with increased statistical power,
which is especially useful when the sample size is very
limited.
min{} −
K∑
k=1
nk
(
log det(k) − trace (S(k)(k))) + P({})
s.t. (1), . . . ,(K) > 0
(2)
The sparsity within each covariance matrix and the simi-
larity across covariance matrices in K groups are encour-
aged by penalty P({}). λ1 and λ2 are two non-negative
parameters to control the enforcement of sparsity and
similarity. In [8], it assumed that the co-expression net-
works across all pair of groups are similar. However, this
assumption does not always hold, especially for discov-
ery of disease stage-specific networks. AD is a slowly
progressive brain disorder that networks are expected
to gradually dissolve or rewire during the progression.
Gene co-expression network in the AD patients may have
become very different compared to that of cognitive nor-
mals after years of progression. Therefore, we modified
the penalty term P({}) to Eq. 3 such that the similarity
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among networks is only enforced for consecutive stages.
For example, networks between CN and EMCI and net-
works between EMCI and LMCI groups are encouraged
to be similar.
P ({}) = λ2
K−1∑
k=1
∑
i=j
∣
∣
∣θ(k)ij − θ(k+1)ij
∣
∣
∣+λ1
K∑
k=1
∑
i=j
∣
∣
∣θ(k)ij
∣
∣
∣
(3)
To solve the modified JGL model, we followed the steps
in [8] using alternating directions method of multipliers
(ADMM) algorithm. With the constraints (k) = Z(k),
the dual variables U(k) are introduced to form scaled
augmented Lagrangian [17].
L ({} , {Z} , {U}) = −
K∑
k=1
nk
(
log det(k)−tr
(
S(k)(k)
))
+ ρ2
K∑
k=1
∥
∥
∥(k) − Z(k) + U(k)
∥
∥
∥
2
F
+ P ({Z}) (4)
The exact solution steps can be referred to the JGL paper
[8]. We modified the step to update {Z} (Eq. 5).
min{Z}
[
ρ
2
K∑
k=1
∥
∥
∥Z(k) − A(k)
∥
∥
∥
2
F
+ P ({Z})
]
(5)
We found that this minimization problem is completely
separable for each element (i,j) in the matrices,
min
Z(1)ij ,...,Z
(K)
ij
ρ
2
K∑
k=1
∥
∥
∥Z(k)ij − A(k)ij
∥
∥
∥
2
F
+ λ1
K∑
k=1
i=j
∣
∣
∣Z(k)ij
∣
∣
∣
+ λ2
K−1∑
k=1
∣
∣
∣Z(k)ij − Z(k+1)ij
∣
∣
∣ (6)
The last penalty term is known as 1-d fused lasso and
penalizes the absolute differences in adjacent values of β
= [Z(1)ij , . . . ,Z(K)ij ]. It can be easily reformulated as ‖Dβ‖1,
where D ⊆ (K−1)×K .
D =
⎡
⎢
⎢
⎣
−1 1 0 . . . 0 0
0 −1 1 . . . 0 0
. . .
0 0 0 . . . −1 1
⎤
⎥
⎥
⎦ (7)
If we first consider λ1 as zero and set y=
[
A(1)ij , . . . ,A(K)ij
]
.
The convex optimization problem becomes a simple 1-d
fused lasso problem (Eq. 8). Note that rank(D)= K − 1.
With a vector s ⊆ K that is orthogonal to all the rows
in D, we can construct Dˆ =
[D
s
]
with rank(Dˆ)=K. Let
θ = (θ1, θ2)T = Dˆβ and θ1 ⊆ K−1, then Eq. 8 will be
transformed into a regular lasso problem (Eq. 9).
min{β}
ρ
2 ||β − y||
2
F + λ2‖Dβ‖1 (8)
min{θ}
ρ
2 ||Dˆ
−1θ − y||2F + λ2‖θ1‖1 (9)
Note that the L1 penalty is only partially applied
to θ1. In order to solve this, we re-write Eq. 9
to a standard form with transformation Dˆ−1θ =[ K\K−1X1 | K\1X2
] [
θ1 | θ2
]T ,
min
θ1,θ2
ρ
2
∣
∣|(y − X1θ1
) − X2θ2
∣
∣ |2F + λ2 ||θ1| |1 (10)
While θˆ2 can be solved as θˆ2 =
(XT2 X2
)−1XT2
(
y − X1θˆ1
)
,
the above equation can be rewritten as
min
θ1
ρ
2
∣
∣|((I − P)y − (I − P)X1θ1)
∣
∣ |2F + λ2 ||θ1| |1
(11)
Where P = X2
(XT2 X2
)−1XT2 . The above equation can be
easily solved using the LARS algorithm [18], from which
we can back-transform to get the solution for Eq. 8: β =
Dˆ−1θ . By applying soft-thresholding to β , we can get the
solution for Eq. 6.
Tuning parameter selection
The tuning parameters λ1 and λ2 in the modified JGL
model were selected using the Akaike information crite-
rion (AIC) (Eq. 12).
AIC(λ1,λ2)=
K∑
k=1
[
nktrace
(
S(k)ˆ(k)λ1,λ2
)
−logdetˆ(k)λ1,λ2+2Ek
]
(12)
Here, ˆ(k)λ1,λ2 is the estimated inverse covariance matrix for
group k under the tuning parameters λ1 and λ2. Ek is the
number of non-zero elements in ˆ(k)λ1,λ2 . We performed a
grid search and λ1 and λ2 with minimal AIC score were
selected.
Performance evaluation
In the subsequent gene co-expression analysis, we refer
our modified JGL model as JGL. To evaluate the per-
formance of JGL, we compared the performance of joint
graphical lasso and traditional graphical lasso, where the
co-expression network of each group is estimated sepa-
rately. Using 1000 permuted datasets, we generated 1000
co-expression networks using JGL and derived a fre-
quency network for each group, where each link has a
value between 0 and 1000 indicating how many times it
is observed to be nonzero. Similarly, we generate another
frequency network for each group using the results from
graphical lasso. Since all the gene expression has been per-
muted and they should be independent from each other,
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the ground truth value for all edges should be zero. Any
nonzero values will be considered as false positives. That
is, the value of each edge in the frequency network indi-
cates its chance to be a false positive. We compared the
performance of JGL and graphical lasso in terms of how
frequently we will observe the false positives using the
permuted data set.
Construction of co-expression network
We applied the modified JGL model to estimate the
co-expression networks of four diagnostic groups simul-
taneously. To evaluate the significance of the estimated
networks, we generated a random data set by running
1000 times of permutation for each gene and each group.
Random data sets were then fed into the modified JGL
model to estimate 1000 × 4 co-expression networks. For
each group, we compared our results against these ran-
domly generated networks and estimated an empirical p
value for each edge in each group. Edges with empiri-
cal P >0.05 were considered insignificant. There were no
insignificant edges identified for CN, EMCI and LMCI
groups. Five edges in AD were found to be insignificant
and were removed from subsequent network comparison
analysis.
Centrality of the network nodes
For every node in the network, four weighted central-
ity values were calculated: weighted degree, weighted
betweeness, weighted closeness and weighted clustering
coefficient. Weighted degree is the sum of number of
connections in terms of the weight of each edge in the
network [19]. R package tnet provides the platform to
calculate weighted centrality of a network. The weighted
degree method proposed method by [20] uses the tuning
parameter alpha to tune the connections and connec-
tion weights. The alpha value of 1 was used to calculate
weighted degree. When an alpha value is 1, it equals to the
definition of weighted degree by [19]. That is, degree is
based on the connection weights of the network [19, 21].
Similarly, betweenness and closeness centrality are based
on the theory of shortest paths in a network. closeness
implies to how close a node is to other nodes in a net-
work. Betweenness is the measure of how often an edge
lies in the path of the other edge. We used alpha value as 1
for both calculation. Finally, clustering coefficient explains
how connected neighbours of a node are in an overall
network. Arithmetic mean measure was used to calculate
the global clustering coefficient of the network as well as
nodal clustering coefficients [20].
Network comparison
We examined and compared all four co-expression net-
works using edge level, node level and network level
metrics. For each edge, its weight indicates the correlation
between two connecting genes. We compared four net-
works by each edge and looked for edges with continu-
ously increasing or decreasing weights from CN to EMCI,
LMCI and AD. Edges with absolute differences >0.01 in
consecutive groups (i.e, (CN- EMCI), (EMCI -LMCI) or
(LMCI - AD)) were considered as potential biomarkers.
We further clustered these edges based on their patterns
of change across four disease stages. Similarly, we also
compared the centrality values of each node and edge to
identify nodes with gradual changes from CN to EMCI,
LMCI and AD.
Results
Comparison of jGL and graphical lasso
We examined the difference of our modified JGL and
graphical lasso in terms of their performance in estima-
tion of co-expression networks based on permuted data
sets. While the permuted data sets are completely ran-
dom, it is expected that none of the genes are correlated.
So all the edges in the estimated networks should have
zero weight. However, with networks estimated using
graphical lasso, we observed that 419 edges in CN, 420
edges in EMCI, 381 edges in LMCI and 250 edges in AD
were frequently (i.e., more than 100 out of 1000 times)
estimated with non zero weights (i.e., false positives)
(Fig. 1). With modified JGL, the weight of all estimated
edges in CN, EMCI and LMCI are zero. In AD group,
299 edges were occasionally (i.e., less than 100 out of
Fig. 1 Frequency network generated using graphical lasso results on permuted data. Edges detected in more than 100 out of 1000 permuted data
sets are plotted for a CN, b EMCI, c LMCI and d AD groups respectively
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Table 3 List of genes with continuous nodal centrality change
Centrality Type Nodes
I C3, MAPK1, PAK1, PRKCH, SLA
ClusCoef
D CALM3, MAPK8, RASA1
I MAPK8, RHOA
Degree
D GRB2, PAK1, PRKCD, PRKCH, PRKCI, SORT1
I None
Betweeness
D CR1, GRB2, RPS6KB1
I DLG4, SRC
Closeness
D PRKCD, RAP1A, RPS6KA1
ClusCoef: clustering coefficient; I: increasing; D: decreasing.
1000 times) estimated to be nonzero and the average
correlation between genes was 0.0023 (Additional file 1:
Fig. S1).
Nodal centrality change during aD progression
There are totally 19 genes showing significant nodal cen-
trality changes from CN to AD. For clustering coefficient,
we found C3, MAPK1, PAK1, PRKCH and SLA with con-
tinuously increasing values from CN to EMCI, LMCI and
AD. In contrast, CALM3, MAPK8 and RASA1 showed
a decreasing pattern. For degree centrality, MAPK8 and
RHOA were found to increase and GRB2, PAK1, PRKCD,
PRKCH, PRKCI, SORT1were found to decrease when sub-
jects progress to a more severe stage. For betweenness,
CR1, GRB2 and RPS6KB1 demonstrated a decreasing pat-
tern. For closeness, DLG4 and SRC were observed to
increase while PRKCD, RAP1A and RPS6KA1 showed a
decreasing pattern. Among these, early centrality changes
are captured by RPS6KB1, MAPK8, PRKCD, PRKCH and
CR1 from CN to EMCI. A complete list of genes with
continuous centrality changes is shown in Table 3. The
detail centrality values of identified genes are in (Addi-
tional file 1: Tables S2–S5.) In Fig. 2 is the co-expression
network module in the CN group that includes only genes
showing gradual nodal changes. RPS6KB1 is observed to
be the top hub.
Co-expression change during aD progression
There are 66 pairs of genes that demonstrated a contin-
uously decreasing or increasing co-expression from CN
to EMCI, LMCI and AD. Based on their change patterns,
we further divided these genes into eight clusters (Fig. 3).
For clusters 1 and 2, correlation between those gene pairs
shows continuous increase or decrease from CN to AD.
For clusters 3 and 4, correlation between those gene pairs
remains relatively stable until LMCI. On the contrary,
gene pairs in clusters 5 and 7 show significant correla-
tion change from CN to EMCI, but then remain stable
until AD. After merging all of these modules, we observed
several hub genes including RPS6KB1 (Ribosomal Protein
S6 Kinase B1), SORT1, MAPK3, textitPRKCD, MAPK8
and GRINA. We further performed an pathway enrich-
ment analysis for these clusters using hyper-geometric
test (Additional file 1: Table S1). Five candidate pathways
are significantly enriched for all clusters except cluster
7 and 8. Among eight gene clusters, early correlation
Fig. 2 Network module with genes showing continuous nodal centrality change from CN to AD
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Fig. 3 Eight gene clusters with distinct patterns of gene co-expression change from CN to AD
changes occurred in five of them, either decreasing or
increasing. We combined these five gene clusters and
formed a gene module as shown in Fig. 4. RPS6KB1 (Ribo-
somal Protein S6 Kinase B1) was found to be the hub
gene, followed by GRINA, MAPK3, PRKCD, MAPK8 and
SORT1.
Global network change during aD progression
Shown in Fig. 5 is the global clustering coefficient change
of co-expression networks from CN to AD. It shows
that the overall weighted clustering coefficient of the co-
expression network remains relatively stable from CN to
EMCI.
Discussion
The superior performance of modified JGL over tradi-
tional graphical lasso, when using the randomly permuted
data, suggests that the similarity constraints on the co-
expression networks of consecutive disease stages can
help effectively control the probability to generate false
positives. Therefore, the differential co-expression pat-
terns identified through JGL results will provide more
accurate information of the altered biological system dur-
ing disease formation. On the other hand, while the high
false positive rate of traditional graphical lasso could be
controlled by the multiple test correction, it will be sub-
ject to the selection of correction method and significance
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Fig. 4 Network module where gene co-expression (i.e.,links) exhibit early change from CN to EMCI. Node color indicates their membership in
different pathways
threshold. In contrast, the similarity constraint used in
JGL played a key role in controlling the false positive rate
even without multiple correction. Therefore, JGL does not
require as large number of permutations as traditional JGL
and is more computationally cost-effective.
The global clustering coefficient change of co-
expression networks from CN to AD suggests strong
structural resilience of the co-expression network in the
early development of AD. However, the global clustering
coefficient drops significantly when patients progress
Fig. 5 Global weighted clustering co-efficient for co-expression networks derived from our JGL model
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from LMCI to AD, which indicates the overall decoupling
of genes in AD-enriched pathways starts dissolve at the
late stage of AD. There is less probability to hold modular
structures within co-expression network when the disease
progresses from less severe to more severe stages.
Among all the genes showing significant changes in
node or edge level metrics, RPS6KB1 has consistently
been observed as the top hub. Given that its central-
ity and co-expression changes occur in the early stage of
AD, it holds great potential to serve as the biomarker for
early diagnosis of AD. RPS6KB1 encodes for a Ser/Thr
(S/T)-directed kinase, 70-kDa S6 kinase (p70S6K), that
plays a crucial role in cell growth, cell differentiation, and
cell cycle control. The p70S6K can phosphorylate tau at
S262, S214, and T212 sites [22]. It is found to be highly
expressed in cerebral cortex and hippocampus, a brain
region affected by AD, according to the Human Protein
Atlas (HPA) [23]. In a large-scale genome wide associa-
tion study (GWAS), it was reported to be a genetic risk
loci for multiple sclerosis [24]. Findings from earlier stud-
ies suggest that the additive effect of alleles in RPS6KB1
and several other genes in tau kinase pathway are asso-
ciated with late-onset of AD in APOE non-e4 carriers
[22, 25].
MAPK8, also known as JNK1, is one of the three pro-
teins in c-Jun N-terminal Kinase family. It is identified to
be involved in the regulation and maintenance of physio-
logical responses in central nervous system [26]. Studies
have also found positive correlation between JNK phos-
phorylation and expression of amyloid beta (Aβ) peptide,
which is a well-known AD hallmark[27].
Other top hub genes that also show early changes
in nodal centrality or co-expression patterns are
MAPK8,MAPK3, GRINA, PRKCD, SORT1, RASA1 and
PAK1. A few studies have reported the association
of these genes with AD. For example, [28] suggests a
potential causative role of P21 activated kinases defects
on the cognitive deficits of AD patients. However, their
coordination has not been previously studied yet. This
work is the first study to reveal how their co-expression
pattern changes during AD progression. Given that the
co-expression and nodal centrality of these genes start
to change in the CN stage, they have great potential
to serve as systems biomarker to capture the bio-
logical alterations in the very early stage of AD and
further help with the development of AD therapeutic
intervention.
Conclusion
We employed a modified joint graphical lasso for estima-
tion of co-expression networks for multiple stages of AD.
Comparing with graphical lasso, JGL accounts for the sim-
ilarity in consecutive disease stages. Our results on ran-
dom data sets shows that it is less likely to generate false
positives. In the subsequent differential co-expression
analysis, we found that the clustering coefficient of the
co-expression network shows significant changes only
when subjects progress from LMCI to AD. Node wise
and edge wise comparison have led to eight gene clusters
that demonstrate continuous changes from CN, EMCI to
LMCI and AD. Particularly, five of them shows differential
co-expression patterns from CN to EMCI. Genes in these
modules could be used as systems biomarkers for early
screening in AD. However, more efforts are warranted to
validate their downstream function.
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